Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis

International policy for treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) relies largely on individual patient data (IPD) from observational studies of patients treated under routine conditions. We prepared guidance on which data to collect and what measures could improve cons...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases Vol. 26; no. 3
Main Authors: Campbell, Jonathon R., Falzon, Dennis, Mirzayev, Fuad, Jaramillo, Ernesto, Migliori, Giovanni Battista, Mitnick, Carole D., Ndjeka, Norbert, Menzies, Dick
Format: Journal Article
Language:English
Published: United States Centers for Disease Control and Prevention 01.03.2020
Subjects:
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Clinical outcomes
Clinical practice guidelines
Data collection
data collection standards
Data dictionaries
evidence-based medicine
Humans
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis
International policy
Laboratories
Meta-analysis
multidrug resistance
Mycobacterium tuberculosis - drug effects
Observational studies
Observational Studies as Topic - standards
Online Report
Patients
Quality Improvement
Rifampin - pharmacology
Rifampin - therapeutic use
therapy data collection
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Pulmonary - drug therapy
Womens health
multidrug resistance
data collection standards
bacteria
therapy data collection
tuberculosis
meta-analysis
statistics and numerical data
TB
RR-TB
antimicrobial resistance
MDR TB
practice guideline
evidence-based medicine
ISSN:1080-6040, 1080-6059, 1080-6059
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:International policy for treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) relies largely on individual patient data (IPD) from observational studies of patients treated under routine conditions. We prepared guidance on which data to collect and what measures could improve consistency and utility for future evidence-based recommendations. We highlight critical stages in data collection at which improvements to uniformity, accuracy, and completeness could add value to IPD quality. Through a repetitive development process, we suggest essential patient- and treatment-related characteristics that should be collected by prospective contributors of observational IPD in MDR/RR TB.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:1080-6040
1080-6059
1080-6059
DOI:10.3201/eid2603.190997